Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer

Experimental Biology and Medicine

Volumn 234, Issue 4, 2009, Pages 372-386

  Chakravarty, Geetika ^a,d   Santillan, Alfredo A ^b   Galer, Chad ^b   Adams, Henry P ^b   El Naggar, Abdal K ^b   Jasser, Samar A ^b   Mohsin, Sayed ^c   Mondal, Debasis ^a   Clayman, Gary L ^b   Myers, Jeffrey N ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Riverside Hospital   (United States)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Image pro; Insulin like growth factor I; Phospho IGF IR; Phospho insulin receptor; Prognostic factor; Thyroid carcinoma; Tissue array; Tyrosine kinase receptor

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER STAGING; DISEASE COURSE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; THYROID CARCINOMA; TUMOR VOLUME;

ADULT; AGE FACTORS; CARCINOMA; GENE EXPRESSION; HUMANS; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; THYROID NEOPLASMS; UP-REGULATION;

EID: 66449132870     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0809-RM-284     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol 94:683-691, 2006. (Pubitemid 44902067)
3. Sherman SI. Thyroid carcinoma. Lancet 361:501-511, 2003. (Pubitemid 36173719)
4. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161:1549-1556, 2003.
5. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90:492-496, 2004. (Pubitemid 38250650)
6. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A. The IGF system in thyroid cancer: new concepts. Mol Pathol 54:121-124, 2001. (Pubitemid 32539600)
7. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153:701-709, 2005. (Pubitemid 41672417)
8. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602, 2004. (Pubitemid 40053427)
9. Bachrach LK, Eggo MC, Hintz RL, Burrow GN. Insulin-like growth factors in sheep thyroid cells: action, receptors and production. Biochem Biophys Res Commun 154:861-867, 1988. (Pubitemid 18208043)
10. Eggo MC, Bachrach LK, Burrow GN. Role of non-TSH factors in thyroid cell growth. Acta Endocrinol Suppl (Copenh) 281:231-237, 1987. (Pubitemid 17110825)
11. van der Laan BF, Freeman JL, Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5:67-73, 1995.
12. Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-4765, 2006.
13. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249-252, 1995.
14. Rubin R, Baserga, R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73:311-331, 1995.
15. Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47, 2007. Epub 2006. (Pubitemid 46220849)
16. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 195:127-137, 2003. (Pubitemid 36588961)
17. Burikhanov R, Coulonval K, Pirson I, Lamy F, Dumont JE, Roger PP. Thyrotropin via cyclic AMP induces insulin receptor expression and insulin co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells. J Biol Chem 271:29400-29406, 1996.
18. Deleu S, Pirson I, Coulonval K, Drouin A, Taton M, Clermont F, Roger PP, Nakamura T, Dumont JE, Maenhaut C. IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Mol Cell Endocrinol 149:41-51, 1999. (Pubitemid 29236222)
19. Van Keymeulen A, Dumont JE, Roger PP. TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells. Biochem Biophys Res Commun 279:202-207, 2000.
20. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 107:873-877, 2003. (Pubitemid 37429826)
21. Baserga R, Resnicoff M, Dews M. The IGF-I receptor and cancer. Endocrine 7:99-102, 1997. (Pubitemid 127483096)
22. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55:2007-2011, 1995.
23. Gydee H, O'Neill JT, Patel A, Bauer AJ, Tuttle RM, Francis GL. Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatr Res 55:709-715, 2004.
24. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, Marra E, Perlino E. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol 8:110-119, 2000. (Pubitemid 30609971)
25. Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K, Ito K. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh) 121:112-120, 1989. (Pubitemid 19167540)
26. Kornprat P, Rehak P, Ruschoff J, Langner C. Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours. J Clin Pathol 59:202-206, 2006. (Pubitemid 43235588)
27. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 33:801-805, 2002. (Pubitemid 34983100)
28. Schillaci R, Galeano A, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF. Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol 130:58-66, 2005. (Pubitemid 40979133)
29. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254, 2002. (Pubitemid 34084698)
30. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790-797, 2004. (Pubitemid 38843361)
31. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34:803-808, 2003. (Pubitemid 37040618)
32. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, Carboni JM, Lee AV. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27:3165-3175, 2007. (Pubitemid 46581327)
33. Balana ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20:34-47, 2001. (Pubitemid 32142336)
34. Burgaud JL, Baserga R. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res 223:412-419, 1996. (Pubitemid 26089098)
35. Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM. Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21:2785-2796, 2002. (Pubitemid 34499375)
36. Pold M, Krysan K, Pold A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett SM. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 64:6549-6555, 2004.
37. Wiseman SM, Loree TR, Hicks WL Jr, Rigual NR, Winston JS, Tan D, Anderson GR, Stoler DL. Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. Arch Otolaryngol Head Neck Surg 129:96-100, 2003. (Pubitemid 36070883)
38. Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem 12:2881-2891, 2005. (Pubitemid 41613364)
39. Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238-13244, 1989. (Pubitemid 19194902)
40. Farrar CE, Huang CS, Clarke SG, Houser CR. Increased cell proliferation and granule cell number in the dentate gyrus of protein repair-deficient mice. J Comp Neurol 493:524-537, 2005. (Pubitemid 41780625)
41. Kapeller R, Chakrabarti R, Cantley L, Fay F, Corvera S. Internalization of activated platelet-derived growth factor receptor-phosphatidylinositol-39 kinase complexes: potential interactions with the microtubule cytoskeleton. Mol Cell Biol 13:6052-6063, 1993. (Pubitemid 23292600)
42. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45:1559-1565, 1997. (Pubitemid 27465476)
43. Colon E, Zaman F, Axelson M, Larsson O, Carlsson-Skwirut C, Svechnikov KV, Soder O. Insulin-like growth factor-I is an important antiapoptotic factor for rat Leydig cells during postnatal development. Endocrinology 148:128-139, 2007. (Pubitemid 46021445)
44. Jones HE, Gee JMW, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI. Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer 12:S173-S182, 2005. (Pubitemid 41395424)
45. Ulfarsson E, Karstrom A, Yin S, Girnita A, Vasilcanu D, Thoren M, Kratz G, Hillman J, Axelson M, Larsson O, Girnita L. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 11:4674-4680, 2005. (Pubitemid 41557184)
46. Lan K-H, Lu C-H, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 1059:70-75, 2005. (Pubitemid 43211612)